Media coverage about Galectin Therapeutics (NASDAQ:GALT) has been trending somewhat positive on Sunday, Accern Sentiment reports. Accern identifies negative and positive press coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Galectin Therapeutics earned a news impact score of 0.09 on Accern’s scale. Accern also gave news articles about the company an impact score of 45.5845291007937 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.

Here are some of the media stories that may have effected Accern’s rankings:

GALT has been the subject of a number of recent analyst reports. HC Wainwright boosted their target price on Galectin Therapeutics from $3.50 to $6.00 and gave the stock a “buy” rating in a research report on Tuesday, November 28th. Roth Capital initiated coverage on Galectin Therapeutics in a research report on Thursday, October 19th. They issued a “buy” rating and a $8.00 target price for the company. ValuEngine lowered Galectin Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Friday, December 1st. Zacks Investment Research raised shares of Galectin Therapeutics from a “hold” rating to a “buy” rating and set a $2.75 price target for the company in a research report on Thursday, November 30th. Finally, Seaport Global Securities reaffirmed a “buy” rating and set a $5.00 price target on shares of Galectin Therapeutics in a research report on Friday, October 6th. One analyst has rated the stock with a sell rating, two have issued a hold rating and three have issued a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average target price of $5.55.

Shares of Galectin Therapeutics (NASDAQ:GALT) opened at $5.87 on Friday. Galectin Therapeutics has a 52-week low of $0.94 and a 52-week high of $6.15. The company has a market cap of $209.20, a PE ratio of -10.67 and a beta of 2.54.

Galectin Therapeutics (NASDAQ:GALT) last released its quarterly earnings results on Tuesday, November 7th. The company reported ($0.13) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.15) by $0.02. analysts predict that Galectin Therapeutics will post -0.52 earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: This report was originally reported by Daily Political and is the property of of Daily Political. If you are viewing this report on another site, it was copied illegally and republished in violation of US and international trademark & copyright laws. The correct version of this report can be viewed at https://www.dailypolitical.com/2018/01/14/galectin-therapeutics-galt-receives-daily-coverage-optimism-score-of-0-09.html.

Galectin Therapeutics Company Profile

Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in drug research and development to create therapies for fibrotic disease and cancer. The Company’s drug candidates are based on its method of targeting galectin proteins, which are mediators of biologic and pathologic functions.

Insider Buying and Selling by Quarter for Galectin Therapeutics (NASDAQ:GALT)

Receive News & Ratings for Galectin Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galectin Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.